The Southeast Cancer Control Consortium (SCCC) application is placed in response to the RFA: Community Clinical Oncology Program. The applicant is a consortium of communities in Eastern Tennessee, Southern Virginia, and North and South Carolina who seek to pool their experience to evolve a productive Community Clinical Oncology Program. The demography of the area reflects low population density, limited socioeconomic and educational development and a black to white population ratio of approximately twice the national average. These participating community oncologists have had experience in clinical trials under the program of the Piedmont Oncology Association (POA) with an accrual of over 750 patients during the past five years. The community team is supported by a local medical oncologist, a cancer committee and a trained oncology nurse protocol coordinator. Each community has participated in quality assurance activities as prescribed by the NCI-CTEP under both the POA and Cancer and Leukemia Group B (CALGB). The opportunity to develop, in association with local agencies, a productive cancer control program will focus on the specific stable population to include education for earlier treatment and compliance in therapy, as well as a program of school age and adult education in prevention. Specific attention will be given to reaching the underprivileged and the black populations. It is anticipated that this group will place 275 patients on clinical trial studies during the first year. The SCCC will develop group cancer control projects via the Oncology Research Center of Bowman Gray School of Medicine and National Cooperative groups (CALGB, NSABP) with which the SCCC is affiliated.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045808-02
Application #
3558711
Study Section
(SRC)
Project Start
1987-07-10
Project End
1990-05-31
Budget Start
1988-06-01
Budget End
1989-05-31
Support Year
2
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Southeast Cancer Control Consortium
Department
Type
DUNS #
876940532
City
Winston-Salem
State
NC
Country
United States
Zip Code
27104
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Cushman, Stephanie M; Jiang, Chen; Hatch, Ace J et al. (2015) Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 21:1078-86
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440

Showing the most recent 10 out of 215 publications